Clinical trials: Occlusion
Coronary Artery Disease
PLATINUM Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions-Pharmacokinetics (PLATINUM PK)
The purpose of this study is to evaluate the safety and effectiveness of the PROMUS Element™ Everolimus-Eluting Coronary Stent System for the treatment of patients with up to 2 de novo atherosclerotic coronary artery lesions.
- Trial name
- PLATINUM PK (NCT01510327)
- Testing
- PROMUS Element Everolimus-Eluting Coronary Stent System, Aspirin, Thienopyridine
- Where
- 5 sites in United States, Japan
- Volunteers
- 22 people
- Sponsor
- Boston Scientific Corporation
Growth Hormone Deficiency
Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers
The purpose of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of HL-032 after oral administration in healthy male volunteers.
- Trial name
- HL-032 (NCT01440686)
- Testing
- Somatropin
- Where
- South Korea
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- HanAll BioPharma Co., Ltd.
Aortic Valve Stenosis
Controlled Arterial Protection to Ultimately Remove Embolic Material
The objective of this study is to demonstrate device feasibility, safety and investigate performance of the EmStop Embolic Protection System when used as indicated in 15 subjects at 2 investigational sites in the U.S.
- Trial name
- CAPTURE-1 (NCT06103591)
- Testing
- The EmStop Embolic Protection System (EmStop System)
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- EmStop Inc
Acute Limb Ischemia
Evaluation of MST-188 in Acute Lower Limb Ischemia
The purpose of this study is to evaluate the safety and efficacy of MST-188 in subjects receiving catheter-directed rt-PA for acute lower limb ischemia and to evaluate whether treatment with MST-188 results in more rapid…
- Trial name
- NCT02093468
- Testing
- MST-188, Saline
- Where
- 4 sites in United States
- Volunteers
- 4 people
- Sponsor
- Mast Therapeutics, Inc.
Peripheral Artery Disease
Humacyte's HAV for Femoro-Popliteal Bypass in Patients With PAD
This study will evaluate how well Humacyte's Human Acellular Vessel (HAV) works when surgically implanted into a leg to improve blood flow in patients with peripheral arterial disease (PAD).
- Trial name
- NCT02887859
- Testing
- Human Acellular Vessel (HAV)
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Humacyte, Inc.
Peripheral Arterial Disease, Critical Lower Limb Ischemia
An All-Comers Observational Study of the MicroStent™ Peripheral Vascular Stent System in Subjects With Peripheral Arterial Disease
Non-randomized, multicenter, combined prospective and retrospective cohort analysis consisting of a single arm treated with the MicroStent™ System.
- Trial name
- HEAL (NCT04110327)
- Testing
- MicroStent
- Where
- 10 sites in Austria, Belgium and 3 more
- Volunteers
- 300 people
- Sponsor
- Micro Medical Solution, Inc.
Coronary Arteriosclerosis, Acute Coronary Syndrome
GRAVITAS: Gauging Responsiveness With A VerifyNow Assay-Impact On Thrombosis And Safety
The objective of the GRAVITAS trial is to determine whether tailored anti-platelet therapy using the Accumetrics VerifyNow P2Y12 assay reduces major adverse cardiovascular events after drug-eluting stent implantation.
- Trial name
- GRAVITAS (NCT00645918)
- Testing
- clopidogrel
- Where
- 82 sites in United States, Canada
- Volunteers
- 2,800 people
- Sponsor
- Accumetrics, Inc.
Critical Limb Ischemia, Peripheral Vascular Disease
Study of Remodulin in Patients With Critical Limb Ischemia With No Planned Revascularization Procedures
The purpose of this study is to assess and compare the safety of continuous and daily subcutaneous Remodulin therapy in patients with critical limb ischemia (CLI) with no planned vascular interventional procedures; and to…
- Conditions
- Critical Limb Ischemia, Peripheral Vascular Disease, Foot Ulcers, Rest Leg Pain
- Trial name
- NCT00060996
- Testing
- Remodulin® (treprostinil sodium) Injection
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- United Therapeutics
Coronary Artery Disease
EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events
EDUCATE is a prospective, multi-center study designed to collect real-world safety and clinical outcomes in subjects receiving one or more Endeavor Zotarolimus-Eluting Stents and either clopidogrel and aspirin or prasugrel and…
- Trial name
- EDUCATE (NCT01069003)
- Testing
- Thienopyridine Therapy, Surveillance Arm
- Where
- United States
- Volunteers
- 2,272 people
- Sponsor
- Medtronic Vascular
Peripheral Arterial Disease
Safety and Feasibility of the Shockwave Lithoplasty® System for the Treatment of Peripheral Vascular Stenosis
To observe early safety and performance of the Shockwave Medical Lithoplasty® System (specifically, Lithoplasty® Catheters: 2.5 x 60mm, 2.75 x 60mm, 3.0 x 60mm, 3.25 x 60mm, and 3.5 x 60mm) in subjects to demonstrate that the…
- Trial name
- BTK (NCT02911623)
- Testing
- Shockwave Lithoplasty® System
- Where
- 4 sites in Austria, Germany and 1 more
- Volunteers
- 20 people
- Sponsor
- Shockwave Medical, Inc.
Critical Limb Ischemia
The DES BTK Vascular Stent System vs PTA in Subjects With Critical Limb Ischemia
Single phased global, prospective, multicenter clinical trial designed to demonstrate a superior patency rate and acceptable safety in below the knee arteries with lesions treated with the DES BTK Vascular Stent System vs.
- Trial name
- SAVAL (NCT03551496)
- Testing
- Drug Eluting Stent - Below the Knee, Standard PTA Control Arm
- Where
- 42 sites in United States, Belgium and 3 more
- Volunteers
- 201 people
- Sponsor
- Boston Scientific Corporation
Coronary Occlusion, Thrombosis (Stent Thrombosis)
XIENCE V Everolimus Eluting Coronary Stent System (EECSS) China: Post-Approval Randomized Control Trial (RCT)
This is a prospective, randomized, active-controlled, open label, parallel two-arm, multi-center, post-approval study descriptively comparing the XIENCE V EECSS to the CYPHER SELECT PLUS Sirolimus-Eluting Coronary Stent System…
- Conditions
- Coronary Occlusion, Thrombosis (Stent Thrombosis), Vascular Disease, Myocardial Ischemia
- Trial name
- NCT01178268
- Testing
- XIENCE V EECSS, CYPHER SELECT PLUS SECSS
- Where
- 2 sites in China
- Volunteers
- 546 people
- Sponsor
- Abbott Medical Devices
Peripheral Arterial Disease
CVI Drug Coated Balloon First In Human Trial
The purpose of this study is to assess safety and the inhibition of restenosis of the CVI Paclitaxel-coated PTA Balloon Catheter in the treatment of de-novo occluded/stenotic or reoccluded/restenotic superficial femoral (SFA) or…
- Trial name
- NCT02110524
- Testing
- Percutaneous Transluminal Angioplasty
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- Spectranetics Corporation
Peritoneal Neoplasms, Intestinal Obstruction
Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis
To evaluate in combination with corticosteroid and local standard medical care the efficacy and safety of long-acting octreotide compared to placebo for the treatment of symptoms of inoperable bowel obstruction in patients with…
- Conditions
- Peritoneal Neoplasms, Intestinal Obstruction, Carcinomatosis
- Trial name
- NCT00332696
- Testing
- Octreotide LAR, Octreotide (Immediate release), methylprednisolone
- Where
- France
- Volunteers
- 64 people
- Sponsor
- Novartis Pharmaceuticals
Myocardial Ischemia
Safety & Efficacy of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia (ATHENA II)
This is a prospective, randomized, placebo-controlled, double blind safety and efficacy clinical trial.
- Trial name
- ATHENA II (NCT02052427)
- Testing
- Celution System
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Cytori Therapeutics
Healthy
Study to Investigate the Safety and Pharmacokinetic Characteristics of LC28-0126 in Healthy Male Subjects
To investigate the safety, tolerability and pharmacokinetic characteristics of LC28-0126 in healthy male subjects
- Trial name
- NCT01737424
- Testing
- LC28-0126
- Where
- South Korea
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Coronary Artery Disease (CAD)
PLASMA Trial: A Dose-Response Study of A-002 In Subjects With Stable Coronary Artery Disease
The study will be conducted at up to 80 centers worldwide and will be a double-blind randomized parallel group placebo controlled study among subjects with stable coronary artery disease (CAD).
- Trial name
- PLASMA (NCT00455546)
- Testing
- A-002
- Where
- 36 sites in United States, Ukraine
- Volunteers
- 400 people
- Sponsor
- Anthera Pharmaceuticals
Aortic Valve Stenosis
Hydra Registry - UK
The study will evaluate the efficacy and safety of transcatheter aortic valve implantation (TAVI) using the Hydra transcatheter aortic heart valve (THV) series, in patients with severe aortic stenosis up to 1-year after the…
- Trial name
- NCT06507579
- Testing
- Hydra transcatheter aortic valve (THV) series
- Where
- 4 sites in United Kingdom
- Volunteers
- 250 people
- Sponsor
- Sahajanand Medical Technologies Limited
Asthma
A Study of 2 Doses of MAP0010 in Adult Asthmatics
The purpose of this study is to examine the blood levels of two doses of MAP0010 (a corticosteroid) and two doses of an approved corticosteroid in adult asthma and safety with twice daily dosing over 7 days.
- Trial name
- P202 (NCT00554970)
- Testing
- MAP0010 low dose, MAP0010 high dose, Budesonide inhalation suspension 0.25mg
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Allergan
Iliac Artery Stenosis, Iliac Artery Occlusion
An Observational Study to Evaluate Safety, Performance, and Clinical Benefit of BeFlow
This international, observational multi-centre study of the device BFI will monitor technical success of the implantation, data regarding clinical performance, clinical benefit, as well as potential unknown side effects pursuant…
- Trial name
- NCT07010354
- Testing
- Stenting
- Where
- 5 sites in Belgium, Switzerland
- Volunteers
- 100 people
- Sponsor
- Bentley InnoMed GmbH